© 2023 BioMarin. All rights reserved.

A dynamic cross-section of business, clinical and biotechnical expertise with a proven track record of providing rapid access to breakthrough therapeutics.

Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases.

Our Pipeline

We maximize the impact of genetic innovation to develop transformative therapies.

We recently presented an update on our pipeline to the investor community. View the replay on our Investor Relations site.

View Now Our Pipeline